Eloralintide
vs Retatrutide.
Compare Eloralintide vs Retatrutide by peptide identity, amylin versus triple-agonist mechanisms, trial results, Phase 3 status, and FDA approval status.
Also searched as Eloralintide peptide vs Retatrutide · LY3841136 vs LY3437943
Eloralintide peptide vs Retatrutide: What is the difference?
Eloralintide and retatrutide are separate investigational once-weekly peptide drugs from Lilly, and no head-to-head trial has compared them. Eloralintide is a single long-acting peptide that selectively activates the amylin 1 receptor. It does not activate GLP-1 or glucagon receptors, despite inaccurate descriptions on some commercial pages. Retatrutide is a synthetic peptide designed to activate GIP, GLP-1, and glucagon receptors. Eloralintide has a peer-reviewed 48-week Phase 2 result and recruiting Phase 3 trials. Retatrutide has Phase 3 TRIUMPH results from longer and different studies. The available evidence cannot establish which drug is better, and neither is FDA approved or a legitimate retail product.
See the useful differences first.
Start with identity, current US status, trial coverage, and the evidence relationship. Then carry the exact pair into a country-aware workspace without losing either record.
Eloralintide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 19 matched NCT records
- Sponsor
- Eli Lilly and Company
Retatrutide
Investigational - not FDA approved
- Route
- Once-weekly subcutaneous injection
- Registry
- 34 matched NCT records
- Sponsor
- Eli Lilly and Company
Eloralintide vs Retatrutide: how direct is the evidence?
No participant in the cited sources was randomized between Eloralintide and Retatrutide. Identity, mechanism, route, trial design, and regulatory status can be compared. Subtracting percentages from separate studies would create a treatment effect the evidence did not test.
Eloralintide
Selective amylin 1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 ENLIGHTEN program recruiting
- Status
- Investigational - not FDA approved
Two evidence records, no shared randomization.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
No randomized head-to-head trialRetatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
The current exact-intervention dataset contains 268 unique NCT records across 13 tracked investigational programs. Counts describe registry coverage, not comparative evidence strength.
matched NCT records
- Recruiting
- 11
- Results posted
- 1
- Recruiting site observations
- 613
matched NCT records
- Recruiting
- 2
- Results posted
- 2
- Recruiting site observations
- 450
Compare the named molecules, active components, sponsors, and receptor strategies.
Compare the studied route, frequency, development phase, and exact program record.
Compare exact approvals, applications, and investigational status in the jurisdiction being checked.
Treat percentages as separate source records. Do not subtract them, divide them into weekly rates, or use the larger value to name a winner.
Use only adverse-event evidence reported for the cited protocol. Separate studies cannot establish which program is safer.
No group result, receptor count, route, approval milestone, or chart position predicts the best choice for one person.
Check both programs in the same market.
Approval, trial activity, product registration, pharmacy rules, and seller authority are country specific. Open both records before treating a status from one market as valid in another.
Eloralintide
Selective amylin 1 receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 ENLIGHTEN program recruiting
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT06230523 · NCT07321886 · NCT07282600 · NCT07369011 · NCT07353931 · NCT07392190 · NCT05295940
Retatrutide
GIP + GLP-1 + glucagon receptor agonist
- Route
- Once-weekly subcutaneous injection
- Stage
- Phase 3 program reporting results
- Status
- Investigational - not FDA approved
- Featured trial anchors
- NCT05929066 · NCT05931367 · NCT05882045
Compare the field, then read the limit.
The comparison matters because both are Lilly programs with large reported weight-loss percentages and once-weekly schedules. Commercial summaries sometimes misclassify eloralintide as a GLP-1 and glucagon dual agonist, then compare it with retatrutide as if one receptor design simply adds GIP. Primary literature shows that this premise is wrong. A responsible comparison must correct the mechanism first and keep every result attached to its actual trial phase, duration, population, dose, estimand, and placebo response.
| Field | Eloralintide | Retatrutide | How to interpret it |
|---|---|---|---|
| Molecular identity | Single long-acting peptide with selective amylin receptor activity | Synthetic peptide triple agonist | Both are peptides, but their sequences, receptor strategies, clinical records, and investigational materials are not interchangeable. |
| Mechanism | Selective amylin 1 receptor agonist | GIP, GLP-1, and glucagon receptor triple agonist | Eloralintide is not a GLP-1 or glucagon agonist, and receptor count cannot establish clinical superiority. |
| Current evidence anchor | Completed 48-week Phase 2 trial in 263 participants | Phase 3 TRIUMPH studies reporting results | Different development phases and trial designs answer different questions and should not be flattened into one ranking. |
| Efficacy-estimand result | Rounded 20% mean change at week 48 in two dose strategies | 28.3% mean change at week 80 for 12 mg in TRIUMPH-1 | The figures share an estimand label but not randomization, duration, population, dose strategy, or placebo response. |
| Phase 3 status | ENLIGHTEN program recruiting, with outcomes not yet available | TRIUMPH program active and reporting Phase 3 outcomes | Recruiting status and reported outcomes are different milestones, and neither one is marketing approval. |
| Current access status | Investigational and not FDA approved | Investigational and not FDA approved | Neither name identifies an approved pharmacy product, prescribing instruction, retail price, or verified online supply route. |
Why the headline numbers do not name a winner.
Eloralintide's Phase 2 publication reported rounded 20% mean weight reduction at week 48 in two dose strategies under an efficacy estimand versus 0.4% with placebo. Lilly's TRIUMPH-1 release reported 28.3% mean weight reduction at week 80 for 12 mg retatrutide under an efficacy estimand versus 2.2% with placebo. Matching the sponsor and estimand label does not create a comparison because the molecules were randomized in separate trials with different phases, durations, participants, dose plans, and missing-data assumptions.
Keep the comparison honest.
- 01
Verify the receptor mechanism from primary literature before accepting any commercial comparison or product description.
- 02
Keep Phase 2 eloralintide and Phase 3 retatrutide findings attached to their exact trial, week, dose, population, and placebo response.
- 03
Do not infer that a shared sponsor, weekly route, or online vial creates head-to-head evidence or authentic clinical material.
A country-specific approval, clinical trial, or matching name does not authenticate an online product or establish access elsewhere. This page contains no treatment recommendation, buying route, personal-use protocol, or affiliate link.
Open the safety and status guide →